Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (ANRO) priced its initial public offering on Feb 5, 2024 at $16.00 per share, raising $128.6M, and listed on NYSE. At the IPO price its market capitalization was about $409.2M. Jefferies was lead-left underwriter, joined by TD Cowen, Stifel and William Blair and others. Cooley advised the company and Latham & Watkins advised the underwriters.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company developing treatments for psychiatric conditions. It uses a Precision Psychiatry Platform that analyzes neurocognitive, EEG and wearable-device data to find brain-based biomarkers that match patients to its product candidates.

Status

IPO

Ticker

ANRO

Exchange

NYSE

Priced

Feb 5, 2024

IPO price

$16.00

Raised

$128.6M

Market cap at IPO price

$409.2M

First filed

Jan 12, 2024

Underwriters

Jefferies, TD Cowen, Stifel, William Blair and Baird

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.